BioXcel gets $260 million from Oaktree and Qatar for Igalmi launch

19 April 2022
bioxcel_large

USA-based BioXcel Therapeutics (Nasdaq: BTAI), a biopharma using artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, has announced strategic financing agreements with funds managed by Oaktree Capital Management and Qatar Investment Authority (QIA).

Under the agreements, Oaktree and QIA will provide up to $260 million in gross funding to support the company’s commercial activities of Igalmi (dexmedetomidine) sublingual film, a product indicated for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder.

"We have never been in a better position to realize our vision of becoming the leading AI-enabled neuroscience company"This financing is also intended to support the expansion of development efforts of BXCL501, which includes a pivotal Phase III program for the acute treatment of agitation in patients with Alzheimer’s disease (AD), and for its additional neuroscience and immuno-oncology clinical programs.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology